AI Article Synopsis
- - The study examined health technology assessment (HTA) outcomes for drug pairs evaluated by agencies in Germany, France, and England/Wales from 2011 to 2018, focusing on both cancer and non-cancer drugs.
- - It was found that GBA and HAS had higher agreement on drug evaluations compared to GBA/NICE and HAS/NICE, with NICE generally rating technologies more positively.
- - Specifically for cancer drugs, GBA's appraisals were often more favorable than those of NICE and HAS, highlighting significant differences in HTA outcomes, especially between cancer and non-cancer evaluations.
Article Abstract
To explore health technology assessment (HTA) outcomes of matched drug pairs by national agencies in Germany (Gemeinsamer Bundesausschuss, GBA), France (Haute Autorité de Santé, HAS) and England and Wales (NICE). We considered published GBA decisions, HAS reports and NICE guidance from January 2011 to June 2018. HTAs of matched pairs were compared overall, and for non-cancer and cancer drugs separately. We further analyzed the role of additional attributes related to cancer therapies. Matched pairs show higher concordance for GBA/HAS than for GBA/NICE and HAS/NICE. Overall, NICE evaluated technologies more favorably than GBA and HAS. GBA appraisals of cancer drugs, however, tended to be more positive than cancer-related recommendations by NICE and HAS. The findings indicate substantial variations in HTAs, although cancer-related outcomes seem to diverge less than non-cancer results.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/cer-2021-0047 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!